CYP19A1 and breast cancer: Aromatase inhibitors, which include letrozole, exemestane and anastrozle, are applied to clinic for postmenopausal women with oestrogen receptor (ER+) and/or progesterone receptor (PR+) early breast cancer as well [8, 9].